Executive Summary
The PTAB instituted inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after finding Imperative Care has shown a reasonable likelihood of success on at least one claim. The dispute centers on whether the claimed “filament” must be flexible, with the Board presently favoring the patent owner’s interpretation.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Imperative Care, Inc. vs Inari Medical, Inc. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
NXP USA, INC. et al.vsParkerVision, Inc.
The PTAB instituted an IPR against NXP’s challenge to ParkerVision’s ’177 patent, focusing on claim 14, and granted NXP’s motion to join the parallel Texas Instruments IPR.
Samsung Electronics Co. Ltd. et al.vsMobile Data Technologies LLC
Samsung has filed an IPR petition challenging Mobile Data Technologies' patent covering mobile device content sharing, asserting obviousness over prior Symbian forum and gaming system references.
TESLA, INC.vsAutonomous Devices, LLC
The PTAB issued a Final Written Decision finding that several original claims were unpatentable over Buibas in view of Sinyavskiy. However, the Board subsequently found the petitioner's substitute claims obvious over combinations of Grotmol and Zhu prior art, leading to further rejection.
Anthony Inc.vsControlTec, LLC
ControlTec and Anthony Doors resolved their co‑development dispute through a settlement agreement that releases all claims and dismisses the related district‑court case. The settlement effectively ends the IPR2025‑00636 proceeding.
Google LLC et al.vsMullen Industries LLC
Google and Samsung’s petition to institute an IPR against Mullen Industries’ patent was denied. The Patent Owner’s response emphasized the Director’s discretionary authority, the parallel district‑court trial, and weak petition merits.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.